ASCO 2021 | Evaluating the prognostic value of PSMA PET/CT in mCRPC

Andrei Gafita, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, discusses the results of the multicenter, retrospective study of PSMA PET/CT as a prognostic tool in men with metastatic castration-resistant prostate cancer (mCRPC). The study aimed to establish the prognostic value of PSMA-imaging and response evaluation criteria to assess response to therapy. By comparing the tumor burden and the presence of lesions, PSMA PET/CT was able to predict overall survival. The results of the study have implications from an efficiency standpoint, but a randomized clinical trial is recommended to validate results. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.